Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct 18;3(10):100788.
doi: 10.1016/j.xcrm.2022.100788.

Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?

Cornelis J M Melief  1
Affiliations
Comment

Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?

Cornelis J M Melief. Cell Rep Med. .

Abstract

Padron et al.1 studied the combination of chemotherapy (gemcitabine and nab-paclitaxel) with either an anti-PD1 (nivolumab) or an anti-CD40 (sotigalimab) antibody in metastatic pancreatic cancer. They showed clinical benefit in individuals with unique biomarkers for each treatment combination.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests C.J.M.M. receives a salary as full-time CSO of ISA Pharmaceuticals, a company focusing on therapeutic vaccination against cancer. He is also entitled to stock options in an ISA-linked management participation plan.

Comment on

References

    1. Padron L.J., Maurer D.M., O’Hara M.H., O’Reilly E.M., Wolff R.A., Wainberg Z.A., Ko A.H., Fisher G., Rahma O., Lyman J.P., et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 2022;28:1167–1177. doi: 10.1038/s41591-022-01829-9. - DOI - PMC - PubMed
    1. Ho W.J., Jaffee E.M., Zheng L. The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 2020;17:527–540. doi: 10.1038/s41571-020-0363-5. - DOI - PMC - PubMed
    1. Carlino M.S., Larkin J., Long G.V. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398:1002–1014. doi: 10.1016/S0140-6736(21)01206-X. - DOI - PubMed
    1. Shiravand Y., Khodadadi F., Kashani S.M.A., Hosseini-Fard S.R., Hosseini S., Sadeghirad H., Ladwa R., O’Byrne K., Kulasinghe A. Immune checkpoint inhibitors in cancer therapy. Curr. Oncol. 2022;29:3044–3060. doi: 10.3390/CURRONCOL29050247. - DOI - PMC - PubMed
    1. Park W., Chawla A., O’Reilly E.M. Pancreatic cancer, a review. JAMA. 2021;326:851–862. doi: 10.1001/jama.2021.13027. - DOI - PMC - PubMed